Background: The male breast cancer (MBC) is a rare disease and represents less than 1% of all malignancies in men and less than 1% of all breast cancers incident. Aim of study: In this descriptive retrospective study we aimed to provide clinico-epidemiological characteristics of MBC. To present the treatment given with respect to DFS , TTP & OS, to identify possible prognostic factors of the disease and the toxicities encountered by the treatment given. Patients and Method:  Out of 11313 cancer patients 3046 were breast cancer; 28 of them were MBC. All patients presented to clinical oncology department in Ain Shams University in the period from January 2008 to December 2014 and follow up till December 2016 Results: The median age of patients was 59 years. Around 90% had hormone receptor positive (estrogen and/or progesterone receptors).Two third of the patients had advanced T-stage (T3 and T4). Infiltrating ductal carcinoma the most common type of histology was encountered. Modified radical mastectomy was the most common (75%) type of surgery done followed by chemotherapy for 21 patients and loco-regional radiotherapy for 20 patients. Tamoxifen was administered in 19 patients. Relapse occurred in 14 patients (50%). The 5-year disease-free survival (DFS) was 21.4%, the 5-year time to progression (TTP) rate was 21.4% and the 5-year old overall survival (OS) rate was 35.7%. Conclusion: There is always a delay in the male patients since the first complaint until they seek medical advice, which results in an advanced disease at presentation.